100%
Validation Report sign off
QA signed Validation Report issued before every go-live
Validated NetSuite implementation for life sciences and medical device teams, with full-service Computer System Validation and Computer Software Assurance aligned to FDA, QMSR, and EU GMP expectations.
100%
QA signed Validation Report issued before every go-live
2 to 4
CSA gap assessment delivered before any validation work begins
Cat. 4
Archer Part 11 E-Signature Module reduces OQ burden versus custom SuiteScript
02.02.26
ISO 13485 incorporated by reference into 21 CFR Part 820
Pharma, biotech, and medical device companies on NetSuite face an FDA inspection environment that is more rigorous and more data driven every year. In 2023, 60 percent of FDA Form 483 observations cited inadequate computer controls. The average cost of an FDA consent decree is $50 million. Validation is no longer a documentation exercise. It is the operating posture that determines whether your NetSuite environment survives inspection.
The Archer CSV and CSA service delivers end-to-end validation documentation: URS, DQ, IQ, OQ scripts, PQ scenarios, RTM, deviation log, and a QA signed Validation Report before your system goes live. The CSA framework, finalized by FDA in September 2025, allows validation effort to scale with risk rather than apply uniformly. Oracle's SOC 2 Type II report covers infrastructure-level IQ. Archer focuses rigorous scripted OQ where regulators look first: audit trail configuration, e-signature SuiteScripts, role separation, and lot traceability.
Post go-live, change control keeps your system in validated state across every NetSuite upgrade, bundle update, and configuration change. For medical device companies, CAPA, complaint, and change control workflows align to QMSR, effective February 02, 2026, with ISO 13485 incorporated by reference.
Every artifact your quality team and an FDA investigator can read. No surprises at go-live.
Validation Services
NetSuite environment audited against FDA CSA and QMSR. Every module classified by GxP criticality. Gap memo delivered before work begins.
Validation Services
URS, DQ, IQ, OQ scripts, PQ scenarios, RTM, deviation log, and QA signed Validation Report for FDA inspection readiness.
Validation Services
CAPA, complaint, and change control workflows aligned to QMSR effective February 02, 2026. ISO 13485, not the old QSR.
Validation Services
Oracle SOC 2 evidence covers infrastructure. Scripted OQ focused on GxP critical functions: audit trail, e-signatures, lot tracking.
Part 11 and Controls
Field-level audit trail on all GxP record types capturing user ID, timestamp in UTC, previous value, and new value. Validated per OQ scripts.
Part 11 and Controls
Pre-validated GAMP Category 4 module with re-authentication, meaning statement, and audit trail. Reduces OQ burden versus custom SuiteScript, which is Category 5.
Part 11 and Controls
Role separation so record creators cannot approve. Positive and negative OQ test cases per role per 21 CFR 11.10(d).
Part 11 and Controls
Each e-signature user submits a Letter of Non-Repudiation to FDA per 21 CFR 11.100(c). Archer guides clients through this step.
Regulatory Coverage
21 CFR Part 11, QMSR, 21 CFR Parts 210 and 211, FDA CSA Guidance, GAMP 5 Second Edition, and EU GMP Annex 11 and 22.
Six phases. Each produces an artifact your quality team and an FDA investigator can both read.
NetSuite environment audited against FDA CSA and QMSR. Every active module, customization, and SuiteScript classified by GxP criticality. Gap memo delivered before any validation work begins, typically within 2 to 4 weeks.
Validation Plan and User Requirement Specification drafted before any configuration work. QA approved. The plan defines scope, risk classification, test strategy, and the artifacts that will be produced.
Installation, Operational, and Performance Qualification executed with risk-calibrated scripted testing. Infrastructure IQ relies on Oracle's SOC 2 Type II report. Scripted OQ focuses on GxP critical functions: audit trail, e-signatures, role separation, and lot traceability.
Requirements Traceability Matrix completed. Every URS requirement traced through design qualification, test scripts, and documented results. Deviations logged, investigated, and closed.
QA signed Validation Report issued, summarizing scope, test results, deviations, and the basis for release. System goes live with full inspection-ready documentation in place.
Change control maintains validated state across every NetSuite upgrade, bundle update, and configuration change. Each change is risk assessed, regression tested where required, and documented to keep the environment inspection ready continuously.
Life sciences and medical device teams that need inspection-ready environments without leaving NetSuite.
Pharma
Pharmaceutical companies on NetSuite need validated environments before commercial distribution and ongoing change control to maintain audit confidence.
Biotech
Biotech companies moving from IND to commercial need validation infrastructure in place before first commercial shipment. CSA aligned scoping shortens the timeline.
CDMO
CDMOs supporting multiple regulated clients need a validated NetSuite environment with lot traceability, batch records, and Part 11 e-signatures.
Medical Device
Device companies need CAPA, complaint, and change control workflows aligned to QMSR, with ISO 13485 incorporated by reference into 21 CFR Part 820.
Cell and Gene Therapy
Cell and gene therapy operations require granular lot traceability, chain of identity controls, and Part 11 compliant audit trails at the transaction level.
Radiopharmaceuticals
Radiopharmaceutical companies face overlapping FDA, DEA, and nuclear regulatory requirements that demand validated controls and audit-ready documentation.
Talk with Archer about the validation artifacts, controls, and change-control path for your NetSuite environment.